Oncology
Following patients after Merck’s nemtabrutinib program ends
When an oncology trial stops, a patient may already have tomorrow’s dose at home and next week’s visit on the calendar. Who calls them, and what instructions can that person give?
By Lampgen Clinical Research

2 min read · estimated
What the source reported
When an oncology trial stops, a patient may already have tomorrow’s dose at home and next week’s visit on the calendar. Who calls them, and what instructions can that person give? Merck is ending development of nemtabrutinib after a benefit-risk review in BELLWAVE-011, a Phase 3 trial in previously untreated CLL and SLL. The decision also covers BELLWAVE-008 and BELLWAVE-010. Merck said it is notifying investigators and directed participants to their study teams and treating physicians to discuss next steps.
A scenario for oncology monitors
At Lampgen Clinical Research, this is a scenario we would put to an oncology CRA candidate. A site has acknowledged the sponsor’s notice. One participant has an unresolved adverse event. Another has missed the coordinator’s call. What would you verify before considering either follow-up complete?
We’d look for someone who can trace the investigator’s instructions to the patient contact record, identify who owns the next attempt, and escalate an unresolved safety question. The investigator guides treatment. The CRA helps make sure the handoff can be verified for every participant, including the person who hasn’t picked up the phone.
What this means for trial teams
For a participant with an upcoming visit, the coordinator needs the investigator’s direction on which assessments still apply. The monitor can compare the revised plan with the visit calendar and check whether the participant received it. For an ongoing adverse event, the monitor can verify the follow-up owner and next assessment against the sponsor’s instructions. These are examples of trial oversight. Merck has not released site-level transition instructions publicly in its announcement.